• Novartis wins EU approval for blood cancer therapy Kymriah expressbpd
    August 29, 2018
    Novartis has received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity.
PharmaSources Customer Service